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The envelope glycoprotein E2 of hepatitis C virus (HCV) is a major component of the viral envelope. Knowledge of its
topologic features and antigenic determinants in virions is crucial in understanding the viral binding sites to cellular
receptor(s) and the induction of neutralizing antibodies. The lack of a robust cell culture system for virus propagation has
hampered the characterization of E2 presented on the virion. Here we report the structural features of hepatitis C virus-like
particles (HCV-LPs) of the 1a and 1b genotypes as determined by various mouse and human monoclonal anti-envelope
antibodies. Our results show that the E2 protein of HCV-LPs reacts with human monoclonal antibodies recognizing
conformational determinants. Monoclonal antibodies (mAbs) specific for the hypervariable region 1 (HVR-1) sequence
reacted strongly with HCV-LPs, suggesting that the HVR-1 is exposed on the viral surface. Several mAbs recognized both
HCV-LPs with equally high affinity, indicating that the corresponding epitopes [amino acids (aa) 192–217 of E1 and aa
412–423, aa 522–531, and aa 640–653 of E2] are conserved in both genotypes and exposed on the surface of the HCV-LP.
The E2 and E1/E2 dimers of 1a bound strongly to the recombinant large extracellular loop (LEL) of CD81 (CD81–LEL) of
human and African green monkey, while the HCV-LP of 1a bound weakly to human CD81–LEL. E1/E2 dimers and the HCV-LPs
of 1b did not bind CD81–LEL, consistent with the notion that CD81 recognition by E2 is strain-specific and does not correlate
with permissiveness of infection. A model of the topology and exposed antigenic determinants of the envelope proteins ofINTRODUCTION
Hepatitis C virus (HCV) infection is a global health
problem affecting an estimated 170 million people world-
wide. The majority of HCV-infected individuals progress
to chronic hepatitis despite the presence of immune
responses. Attempts to elucidate the viral mechanisms
of persistent infection and host factors necessary for
viral clearance have been hampered by the lack of a
robust cell culture system for virus propagation and con-
venient animal models.
HCV, a member of the Flaviviridae family, is an envel-
oped virus with a positive-strand RNA genome of 9.6
kb. A considerable genetic heterogeneity with more than
six distinct genotypes exists among different HCV iso-
lates; however, genotypes 1a and 1b are the most prev-
alent worldwide (Bukh et al., 1995). The viral genome
encodes a single polyprotein of approximately 3000
amino acids (aa) that is processed into the structural and
nonstructural proteins by host and viral proteases, re-
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dressed at Liver Diseases Section, National Institute of Diabetes and
Digestive and Kidney Diseases, NIH, Building 10, Room 9B06, 10All rights reserved.spectively. The putative structural proteins [the core and
the two envelope glycoproteins (gp), E1 and E2] are
located within the N-terminus of the polyprotein while the
nonstructural proteins reside within the C-terminal part
(for a review, see Bartenschlager and Lohmann, 2000).
HCV E2 glycoprotein extends from aa 384 to 746 of the
polyprotein and contains a region of extreme variability
at the amino-terminal domain (aa 384–411), the so-called
hypervariable region 1 (HVR-1). E2 protein is considered
to be important for initiation of infection by binding to a
cellular receptor(s) and is also known as one of the
major antigenic targets of host immune responses. Se-
quence analyses of different HCV isolates and sequen-
tial studies of virus isolates from infected patients sug-
gest that the HCV E2 protein under immune selection
results in selection of variants within the HVR-1 (Bukh et
al., 1995; Kato et al., 1990; Weiner et al., 1992). Antibodies
to HVR-1 appeared to mediate viral neutralization in vitro
and in a chimpanzee protection study (Shimizu et al.,
1996; Farci et al., 1994). However, antibodies to HVR-1
tend to be isolate-specific and over time drive the selec-
tion of new viral variants that are not recognized by the
preexisting antibodies (Shimizu et al., 1994).
The precise mechanism of HCV binding and entry intoHCV is proposed. © 2002 Elsevier Science (USA)
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cells is poorly understood and CD81, a tetraspanin pro-
tein, has been proposed as a putative HCV receptoral epito
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based on its interaction with a truncated form of the E2
protein (Pileri et al., 1998). Nonetheless, there is accu-
mulating evidence that binding between E2 and CD81 is
strain or isolate specific (Yagnik et al., 2000) and does not
necessarily confer susceptibility to HCV infection, at
least in tamarin (a small New World monkey) and African
green monkey (AGM). HCV E2 protein binds with higher
affinity to tamarin CD81 than to human CD81 (Allander et
al., 2000; Meola et al., 2000) and to a lesser extent to
AGM CD81 (Allander et al., 2000). At present, direct
evidence that CD81 mediates HCV virion binding and
entry into cells has not been established. Wu¨nschmann
et al. (2000) showed that CD81 inhibited the binding of E2
protein, but not HCV virion, to Molt-4 cells. Taken to-
gether, these results suggested either that there are
conformational differences in E2 proteins between the
truncated soluble form and the virion form or that HCV
virions may employ another cellular receptor(s) for viral
entry.
To date, as the ultrastructural features of the HCV
virion remain elusive, the knowledge of antigenic deter-
minants of HCV envelope proteins displayed on the viral
particles is important for designing specific antiviral
drugs and vaccines. Several groups have generated a
panel of mouse and human anti-E2 monoclonal antibod-
ies (mAbs) and mapped their epitope recognition sites
within the E2 protein (Dubuisson et al., 1994; Flint et al.,
1999; Habersetzer et al., 1998; Hadlock et al., 2000; Ow-
sianka et al., 2001). We have previously reported the
generation of a recombinant baculovirus expressing
HCV-like particles (HCV-LPs) containing the structural
proteins of HCV derived from the J strain (1b genotype)
(Baumert et al., 1998). As part of our effort to characterize
HCV-LP as a model system for the HCV virion, the goal of
this study was to map the topology of envelope proteins
on HCV-LPs using various anti-envelope monoclonal an-
tibodies with well-defined epitopes. In addition, the in-
teraction of HCV-LPs with human CD81 molecules was
investigated.
RESULTS AND DISCUSSION
Recombinant baculoviruses produce HCV-LPs of 1a
and 1b
Generation of HCV-LP of the 1b genotype (J strain) has
been described previously (Baumert et al., 1998). Using
the same approach, recombinant baculovirus expressing
HCV-LP of the 1a genotype was generated from the H77
strain of HCV (Kolykhalov et al., 1997). Both the 1a and 1b
HCV sequences used for generation of HCV-LPs were
derived from clones that have been shown to be infec-
tious in chimpanzees (Kolykhalov et al., 1997; Thomson
et al., 2001). Insect cells (Sf9) were infected with the
recombinant baculovirus at m.o.i. 5 and HCV-LPs were
harvested at 3 days postinfection. HCV-LPs were par-
tially purified by equilibrium 20–60% sucrose gradient
centrifugation as described (Baumert et al., 1998). Both
recombinant particles formed double-shelled particles
with a predominant size of 50 nm in diameter as ana-
lyzed by electron microscopy (Baumert et al., 1998;
Triyatni et al., manuscript in preparation).
HCV-LPs assume a proper E2 conformation
Initially, we tested the antigenicity of HCV-LPs against
several mouse anti-E1 and -E2 monoclonal antibodies
specific for linear and conformational epitopes. As
shown in Fig. 1, HCV-LP 1a was highly reactive against
two anti-E2 antibodies, H2 and H53, that recognize con-
formational epitopes present in E2 of the noncovalently
linked E1/E2 heterodimer of the HCV 1a genotype
(Deleersnyder et al., 1997; Cocquerel et al., 1998). The
recognition of HCV-LPs by these antibodies suggests
that the E2 protein presented on the recombinant HCV
particles adopts the proper conformation. Since a similar
antibody specific for the E2 protein of the 1b genotype is
not available, such an analysis for the E2 form on
HCV-LP 1b is not possible.
Recognition of HCV-LPs of 1a and 1b genotypes by
anti-E1 and anti-E2 monoclonal antibodies
Next, we analyzed the antigenicity of both types of
HCV-LPs with a panel of anti-E1 and -E2 monoclonal
antibodies. As shown in Table 1, certain regions within
the E1/E2 proteins of HCV-LP 1a and 1b were equally
recognized by similar antibodies which may reflect the
highly conserved regions in both genotypes (aa 192–217
FIG. 1. Reactivities of mouse anti-E1 and -E2 mAbs to HCV-LPs.
HCV-LPs of the 1a or 1b genotypes were captured on a GNA-coated
ELISA plate as described under Materials and Methods. The plate was
then incubated with various mouse anti-E1 or -E2 monoclonal antibod-
ies, anti-E1 (A4) at 6 g/ml or anti-E2 (AP33 at 6 g/ml, H2 and H53
culture medium at 1/100 dilution), or mouse anti-GST IgG as a negative
control. Bound antibodies were detected by peroxidase-labeled goat
anti-mouse IgG. The results presented are representative of three
independent experiments.
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TABLE 1
Reactivities of Anti-E1/-E2 Monoclonal Antibodies against HCV-LPs 1a and 1b
MAb Protein Amino acid
Epitopesa
H strain 1a sequence








A4 E1 197–207 SSGLYHVTNDC 6,400 ND
VSGIYHVTNDC 100
YEVRNVSGIYHVTNDCSNS
159 E1 192–210 YQVRNSSGLYHVTNDCPNS 1,600 ND
YEVRNVSGIYHVTNDCSNS 3,200
SIVYEAA
3D5/C3 E1 211–217 SIVYEAA 1,600 ND
SIVYEAA 1,600
ETHVTGGS
7/59 E2 384–391 ETHVTGGS 800 No
(HVR-1) HTHVTGGR 50
9/27 E2 384–410 Conformational 3,200 50 No
(HVR-1)
QLINTNGSWHIN
3/11 E2 412–423 QLINTNGSWHIN 400 No
QLVNTNGSWHIN 100
QLINTNGSWHVN
AP33 E2 412–423 QLINTNGSWHIN 25,600 ND
QLVNTNGSWHIN 25,600
GSWHINRTALNCND
H E2 418–431 GSWHINRTALNCND 50 ND
GSWHINRTALNCND 50
SLNTGWLAGLFY
1/39 E2 432–443 SLNTGWLAGLFY 200 No
SLQTGFIAALFY 50
GWLAGLFY
2/69a E2 436–443 GWLAGLFY 50 No
GFIAALFY 50
GWLAGLFYHHK
7/16b E2 436–447 GWLAGLFYHHK 50 Yes
GFIAALFYAHR 50
DFDQGWGP
AP320 E2 464–471 DFAQGWGP 200 ND
EFAQGWGP 50
DFDQGWGP
6/1a E2 464–471 DFDQGWGP 50 No
KFAQGWGP 50
DQRPYCWHYPP
6/41a E2 481–491 DQRPYCWHYPP 50 Yes
DQRPYCWHYAP 50
DFDQGWGPISYA
AP109 E2 464–475 DFAQGWGPISYA 50 ND
EFAQGWGPITHD 50
SGAPTYSW
3E5-1 E2 522–529 SGAPTYSW 25,600 ND
FGAPTYSW 25,600
APTYSWGA
9/75 E2 524–531 APTYSWGA 3,200 No
APTYSWGE 3,200
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of E1 and aa 412–423, aa 522–531, and aa 640–653 of E2).
However, several antibodies reacted with higher affinity
to HCV-LP 1a than to that of the 1b genotype because
they were raised against the 1a E2 protein and some
sequence heterogeneity exists within the recognized
epitopes between 1a and 1b (Flint et al., 1999). For
instance, 3/11, 1/39, and AP320 antibodies (recognizing
aa 412–423, aa 432–443, and aa 464–471 of E2, respec-
tively) appeared to behave this way.
As one of the major antigenic targets of the humoral
response, the HVR-1 of the E2 protein (aa 384–410)
should be exposed on the surface of HCV-LPs. Indeed,
this was the case for HCV-LP 1a as it was recognized by
two anti-HVR-1 antibodies, 7/59 and 9/27. However,
these antibodies failed to recognize HVR-1 of HCV-LP 1b,
most likely due to substantial sequence heterogeneity. In
support of this notion, it has been shown that 3C7-C3, a
broadly reactive anti-HVR 1 monoclonal antibody that
can specifically capture HCV virions, also recognizes
HCV-LPs of both 1a and 1b (1a more strongly than 1b)
(Cerino et al., 2001; and our unpublished data).
As mentioned above, three regions of E2 (aa 412–423,
aa 522–531, and aa 640–653) are likely exposed on the
surface of HCV-LPs because the corresponding antibod-
ies (AP33, 3E5-1, 9/75, and ALP98) reacted to both types
of HCV-LPs with high affinity. Several antibodies (H,
2/69a, 7/16b, 6/1a, 6/41a, AP109, 6/53, and ALP1) failed to
recognize both types of HCV-LPs. Of particular interest,
7/16b, 6/41a, and 6/53 are known to block E2–CD81
interaction (Flint et al., 1999). These results suggest that
either the corresponding epitopes are not accessible on
HCV-LP or the affinities of these antibodies against the
antigenic determinants are weak and therefore not de-
tected by our assay. For example, AP33 and 3/11 anti-
bodies recognized similar epitopes (aa 412–423) of E2,
but only AP33 showed very strong affinity to both types of
HCV-LPs (titer of 25,600) and 3/11 reacted only weakly
(titer of 400). Likewise, a significant difference in reactiv-
ity between 3E5-1 and 9/75 antibodies that recognized
overlapping epitopes between aa 522 and 531 of E2 (titer
of 25,600 vs 3200) also exists. However, many of these
antibodies have been shown to bind strongly to dena-
tured and various truncated forms of E2 and E1/E2 (Flint
et al., 1999), suggesting that some of the epitopes are not
exposed on the HCV-LP. Our observations are largely
supported by a recent report (Wellnitz et al., 2002) on
reactivities of various mouse monoclonal antibodies to
HCV-LP 1a. However, they did not compare in great
detail the different reactivities between the HCV-LPs of
1a and 1b.
Conformational human anti-E2 monoclonal antibodies
recognize HCV-LPs
Previously, we have shown that serum samples con-
taining anti-HCV antibodies from HCV-infected individu-
als (genotypes 1a, 1b, 2, 3, 4, and 5a/b) were highly
reactive against HCV-LP 1b in ELISA (Baumert et al.,
1999), suggesting that epitopes presented on the enve-
lope proteins of HCV-LP were broadly conserved among
different genotypes. Hence, the recent isolation of
HmAbs which recognize conserved conformational
epitopes within the HCV E2 protein among different ge-
notypes (Hadlock et al., 2000) allowed us to determine
whether similar epitopes were present on HCV-LPs.
Eight HmAbs, CBH-2, -4G, -5, -7, -8c, -8e, -11, and -17,
exhibited reactivities with either or both recombinant
particles, while no reactivity was observed with the con-
trol HmAb (R04, specific to a cytomegalovirus protein)
(Fig. 2). Although the antigenic binding sites of these
HmAbs have not been mapped, they are thought to
recognize conformational epitopes on the E2 protein.
The HmAbs with the highest levels of reactivity to both
types of HCV-LPs were CBH-7 and CBH-8c, followed by
TABLE 1—Continued
MAb Protein Amino acid
Epitopesa
H strain 1a sequence








6/53 E2 544–551 PPLGNWFG 50 Yes
PPQGNWFG 50
LDAACNWTRGERCD
ALP98 E2 640–653 LEAACNWTRGERCD 12,800 ND
LNAACNWTRGERCD 12,800
RGERCDLEDRDR
ALP1 E2 648–659 RGERCDLEDRDR 50 ND
RGERCNLDDRDR 50
a Underlined sequence represents amino acids that are different from the mapped epitopes.
b Titer of mAbs was determined as the serial dilution that gave OD405 nm just below the cut-off (signal to noise ratio 2.5).
c Flint et al. (1999). ND, not determined.
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CBH-5, -17, -4G, -11, -2 and -8e. The order of affinity of
HmAbs shown against HCV-LPs was in general accor-
dance with the previous study on E2 (Hadlock et al.,
2000), suggesting that the epitopes recognized by these
antibodies were conserved in genotypes 1a and 1b of
HCV. However, we also observed minor differences be-
tween the reactivities of HmAbs with 1a and 1b HCV-LPs
and those with 1a and 1b E2 protein expressed by the
vaccinia expression system (Hadlock et al., 2000). Se-
quence heterogeneity and a disparate expression sys-
tem may explain the differences.
HCV-LPs of 1a interact weakly with CD81
The ability of HCV-LPs to bind human CD81 was ana-
lyzed on an ELISA plate coated with the soluble GST
fusion protein of the large extracellular loop (LEL) of
human (wild-type or mutant T163A), AGM, or mouse
CD81 (CD81–LEL). It has been shown that the T163A
mutant, in comparison to the wild-type, of human CD81
showed a higher binding affinity to E2 protein (Higgin-
bottom et al., 2000). As a negative control, the plate was
also coated with GST protein alone. CD81 binding to
HCV-LPs was compared to various forms of E2 protein:
mammalian-derived truncated E2 (E2710) of 1a and 1b and
the E1/E2 proteins of 1a (Choo et al., 1994) and 1b
genotypes (Baumert et al., 1999). While the mammalian-
derived E2710 and HCV-LPs were derived from two differ-
ent HCV 1a strains (PT and H77 strains, respectively), the
amino acid divergence between the two strains is 5%
and therefore should not contribute to any significantly
different binding property. The 1b proteins were all de-
rived from the J strain (Kato et al., 1990). As seen in Fig.
3, in contrast to a strong interaction with truncated E2 or
E1/E2 proteins of the 1a genotype, the wild-type and
FIG. 2. Reactivities of anti-E2 HmAbs to HCV-LPs. HCV-LPs 1a and 1b were captured onto a GNA lectin-coated ELISA plate as described under
Materials and Methods and then the plate was incubated with HmAbs at the indicated concentrations above. As a control, R04, a HmAb to
cytomegalovirus protein, was used. Bound antibodies were detected by HRP-conjugated goat anti-human IgG. The results presented are represen-
tative of three independent experiments.
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T163A mutant human CD81 bound HCV-LPs 1a only at
high concentrations. The large amount needed for HCV-
LPs might be partly because the E2 consists of only a
small proportion of the total protein in the preparation.
Based on Western blot analysis using various known
quantities of purified truncated E2 protein as standards,
we estimated that E2 consisted of 1/20 of total protein
in the HCV-LP preparation (data not shown). However
even if we correct for the amount of E2 protein, the
binding of CD81 to the HCV-LP1a is still much weaker
than that to the E1/E2 proteins of genotype 1a. It is worth
noting that E1/E2 of 1a also bound AGM CD81 with
comparable affinity to human CD81, confirming the pre-
vious findings that the E2 protein binds CD81 proteins of
AGM and tamarin in addition to that of human (Allander
et al., 2000; Meola et al., 2000). However, the T163A
mutant human CD81 did bind to truncated E2 and
HCV-LP 1a with higher affinity than wild-type CD81. The
E1/E2 and HCV-LPs of 1b genotype did not bind to CD81.
No interaction was found between mouse CD81–LEL or
GST and all forms of E2 protein tested.
The weak interaction observed between HCV-LPs and
CD81 is very unlikely due to the glycosylation difference
of the E2 glycoprotein of HCV-LPs in insect cells. It has
been demonstrated previously that the truncated E2 pro-
tein derived from both mammalian (Higginbottom et al.,
2000) and insect cells (Chan-Fook et al., 2000) binds
CD81, indicating that the glycan composition of the E2
protein has no direct effect on this interaction. In our
hands, insect-derived E2715 of 1a genotype also dis-
played a high affinity to human CD81 (data not shown).
Previously, Flint et al. (1999) proposed that CD81 bind-
ing sites on the E2 protein reside within aa 480–493
and 544–551, based on the ability of the corresponding
anti-E2 monoclonal antibodies, 6/41a and 6/53, respec-
tively, to block E2–CD81 interaction. However, our results
showed that these antibodies failed to recognize both
types of HCV-LPs. One plausible explanation is that the
CD81 binding sites (as present on the truncated E2
protein) are less accessible on HCV-LPs. The weak in-
teraction between HCV-LP 1a and CD81 may also ex-
plain our finding that neither CD81 nor anti-CD81 anti-
body was able to block HCV-LP binding to several hu-
man hepatic cell lines (Triyatni et al., manuscript in
preparation). Therefore, it is possible that CD81 may not
directly mediate the binding of HCV virions to suscep-
FIG. 3. Interaction of CD81 with truncated E2, E1/E2 proteins, and HCV-LPs. An ELISA plate was coated with GST fusion protein of CD81–LEL of
human (wild-type and mutant T163A), AGM, or mouse as described under Materials and Methods. Truncated E2, E1/E2, or HCV-LPs from 1a and 1b
genotypes were then added to each well and incubated at 4°C overnight. The plate was incubated with anti-E2 monoclonal antibody AP33 (6 g/ml),
followed by peroxidase-labeled goat anti-mouse IgG. Bound antibodies were detected as described in the legend to Fig. 1. The results presented are
representative of three independent experiments.
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tible cells. This possibility has been raised recently
(Wu¨nschmann et al., 2000). Hence, the CD81–E2 interac-
tion may represent some alternative effect of the virus on
cells and may play an important role in the pathogenesis
of HCV infection, e.g., autoimmune manifestations (Wack
et al., 2001), and viral evasion from the immune system.
CD81–E2 engagement has been shown to inhibit natural
killer cell activation and interferon- production (Crotta et
al., 2002), presumably as one mechanism of HCV to
establish persistent infection.
Taken together, our results described in this study
demonstrate that the envelope proteins of HCV-LPs dis-
play broadly conserved epitopes that are recognized by
mouse and human anti-HCV antibodies. Based on the
reactivities of various monoclonal antibodies tested, we
proposed a model for the topology of envelope proteins
on HCV-LP (Fig. 4). Some of the exposed regions fea-
tured were in accordance with their hydrophilic charac-
teristics as described by Yagnik et al. (2000). Undoubt-
edly, additional information such as the three-dimen-
sional structure of HCV-LP with antibody labeling would
be warranted to ascertain the structure–antigenic rela-
tionship presented here. Although it remains to be seen
whether the antigenic profiles of HCV-LP resemble those
of the HCV virion, our data are beginning to provide a
road map for the putative structure of the HCV virion.
MATERIALS AND METHODS
Anti-HCV envelope monoclonal antibodies
Anti-E1 (A4) and anti-E2 (H) antibodies were provided
by H. Greenberg (Dubuisson et al., 1994); anti-E2 anti-
bodies (H2 and H53) were from J. Dubuisson (Deleersny-
der et al., 1997; Cocquerel et al., 1998). 3D5/C3 and 3E5-1
(anti-E1 and anti-E2 antibodies, respectively) were from
M. Houghton (personal communication). The anti-E1 an-
tibody 159 was from J. Lau. Anti-E2 monoclonal antibod-
ies (raised against the Glasgow strain of 1a genotype)
AP33, AP320, AP109, ALP98, and ALP1 were from A.
Patel (Glasgow, UK) (Owsianka et al., 2001). Anti-E2
monoclonal antibodies (raised against H77 strain of 1a
genotype) 7/59, 3/11, 2/69a, 9/27, 1/39, 6/1a, 7/16b, 6/41a,
9/75, and 6/53 were from J. McKeating (Reading, UK)
(Flint et al., 1999).
FIG. 4. A topologic model of the envelope proteins of HCV-LP. The diagram depicts the topologic model of E1/E2 proteins of HCV-LP based on the
reactivities of anti-E1 and anti-E2 monoclonal antibodies as shown in Table 1 (not drawn to scale). The glycosylation sites in E1 (Meunier et al., 1999),
some of the putative glycosylation sites in E2 (Yagnik et al., 2000), and the transmembrane domains (black boxes) at the carboxy termini of E1 (aa
353–383) and E2 (aa 718–746) (Op De Beeck et al., 2001) are also shown. The proposed surface-exposed regions of E1 and E2 are shown with various
antibody binding sites.
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E1/E2 ELISA
A 96-well ELISA plate (Immulon, Dynex Tech, VA) was
coated with 100 l (20 g/ml in PBS) of GNA (lectin from
Galanthus nivalis, Sigma) at 37°C for 3 h and then
blocked with 150 l of 4% goat serum (in 5% skim milk–
PBS) for 3 h at RT. HCV-LPs (of 1a or 1b genotype) were
then added and incubated at 4°C, overnight. Various
mouse anti-E1 or -E2 monoclonal antibodies were then
added and the plate was incubated for 3 h at 37°C. As a
negative control, mouse anti-GST IgG was used. Then
100 l of peroxidase-labeled goat anti-mouse IgG
(Kirkegaard & Perry Laboratories, Gaithersburg, MD) at a
dilution of 1/1000 was added and incubated for 1 h at
37°C. Bound antibodies were detected by the addition of
ABTS Microwell Peroxidase Substrate System (KPL) and
measured on an ELISA reader (Bio-Rad) at an optical
density of 405 nm. Plates were washed six times with
PBS between each step and, after the addition of the
primary antibodies, with PBS–0.05% Tween 20. All dilu-
tions were made in PBS containing 5% skim milk. To
determine the reactivity of HmAb to HCV-LPs, HCV-LPs
1a or 1b were captured onto a GNA lectin-coated ELISA
plate as described above. After the plate was washed,
HmAbs at various concentrations were added and incu-
bated for 3 h at 37°C. As a control, R04, a HmAb to
cytomegalovirus protein, was used. Bound antibodies
were detected by HRP-conjugated goat anti-human IgG.
CD81 ELISA
An ELISA plate was coated with 100 l (10 g/ml in
PBS) of GST fusion protein of CD81–LEL of human (wild-
type and mutant T163A), AGM, or mouse at 4°C overnight
and then blocked with 150 l of 4% goat serum (in 5%
skim milk–PBS) for 3 h at RT. Different sources of E2
protein (truncated E2, E1/E2, and HCV-LPs) from the 1a
and 1b genotypes were added to each well and incu-
bated at 4°C overnight. The plate was then incubated
with anti-E2 monoclonal antibody AP33 (6 g/ml) for 3 h
at RT, followed by peroxidase-labeled goat anti-mouse
IgG at a dilution of 1/1000 for 1 h at RT. Bound antibodies
were detected as for the E1/E2 ELISA.
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